JAMA Network Open
October 1, 2026
Kim Madden, Breanne Flood, Imad Kashir et al.
Psilocybin has received increased attention as a potential therapeutic intervention, but it is unclear whether news media reporting reflects the strengths and limitations of the clinical trial evidence. To describe the annual counts of published clinical trials of therapeutic psilocybin and contemporaneous media articles and compare tone, efficacy, and safety messaging. This systematic review...
Psychedelics
October 1, 2026
Lorenzo Miller, Cordelia Kuiper Rauch, Keren Chen et al.
Background Psilocybin-assisted therapy has shown robust antidepressant effects among individuals with major depressive disorder (MDD); however, mechanisms of the treatment remain unclear. Depression has been associated with diminished feelings of connectedness to oneself, others, and the world, and psilocybin is thought to facilitate connectedness. This analysis of an open-label trial of...
Psychedelics
October 1, 2026
Benjamin R. Lewis, Eric L Garland, Zach Schwartz et al.
Background Psychedelic-assisted psychotherapy (PAP) has demonstrated great promise for a variety of mental health problems. Many clinicians and researchers who are engaged in providing PAP report personal experiences with psychedelics; these experiences are often positive. Still, there are ongoing questions regarding the relevance of therapists personal experience with psychedelic drugs for the...
Journal of Consciousness Studies
October 1, 2026
Adam Greif, Gabriela Bezáková
Psychedelic-assisted therapy occasions mystical experiences and their intensity often predicts therapeutic outcomes. Owing to their spiritual import, psychedelics have been linked to supernatural thinking, religions, and cults. Several authors within the psychedelic field argue these associations render the field scientifically and ethically questionable, with some calling for the ‘mystical...
Psychosomatic Medicine and General Practice
September 30, 2026
Viacheslav Zaika, Yan Tytarenko
Background and aims. Depression is highly prevalent, and 30%–60% of patients do not respond adequately to standard therapy. Ketamine-assisted psychotherapy (KAP) is a promising approach, but psychiatric contraindications remain unstandardized. This study aimed to systematize mental health-related contraindications to ketamine-assisted therapy. Material and methods. We reviewed 74 publications,...
September 30, 2026
Abraham Peled
preprint
AbstractPsychiatry is the only branch of medicine that still diagnoses without reference to the organ it treats. Psychiatry: The Case for Starting Over argues that this is a structural failure rather than a temporary gap. The descriptive nosology inherited from Kraepelin and formalized in the DSM achieved diagnostic reliability at the cost of validity. Its categories were assembled by committee...
September 29, 2026
Paul S. Links
Considere la neuromodulación para pacientes con TLP y depresión mayor comórbida que no hayan respondido a antidepresivos y otros medicamentos. La evidencia de revisiones sistemáticas respalda un papel complementario en estos casos. Al usar ketamina en el TLP, vigile cuidadosamente la aparición de conductas desinhibidas y el aumento de la ideación suicida. Los reportes de casos han documentado...
September 29, 2026
Paul S. Links
Envisagez la neuromodulation pour les patients atteints de trouble de la personnalité borderline présentant une dépression majeure comorbide et un échec des antidépresseurs et d'autres médicaments. Les données d'une revue systématique soutiennent un rôle complémentaire dans ces cas. Lors de l'utilisation de la kétamine dans le trouble de la personnalité borderline, surveillez attentivement les...
September 29, 2026
Paul S. Links
Considere a neuromodulação para pacientes com TPB e depressão maior comórbida que não responderam a antidepressivos e outras medicações. Evidências de revisões sistemáticas apoiam um papel complementar nesses casos. Ao utilizar cetamina no TPB, monitore cuidadosamente comportamentos desinibidos e aumento da ideação suicida. Relatos de caso documentaram ambas as reações como efeitos negativos. A...
September 29, 2026
Paul S. Links
Considerare la neuromodulazione per i pazienti con disturbo borderline di personalità e depressione maggiore in comorbilità che non hanno risposto agli antidepressivi e ad altri farmaci. Le evidenze delle revisioni sistematiche supportano un ruolo supplementare in questi casi. Quando si utilizza la ketamina nel disturbo borderline di personalità, monitorare attentamente eventuali comportamenti...